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Abstract
Background: Nipah virus (NiV) is an emerging paramyxovirus distinguished by its ability to cause
fatal disease in both animal and human hosts. Together with Hendra virus (HeV), they comprise the
genus Henipavirus in the Paramyxoviridae family. NiV and HeV are also restricted to Biosafety Level-
4 containment and this has hampered progress towards examining details of their replication and
morphogenesis. Here, we have established recombinant expression systems to study NiV particle
assembly and budding through the formation of virus-like particles (VLPs).
Results: When expressed by recombinant Modified Vaccinia virus Ankara (rMVA) or plasmid
transfection, individual NiV matrix (M), fusion (F) and attachment (G) proteins were all released
into culture supernatants in a membrane-associated state as determined by sucrose density
gradient flotation and immunoprecipitation. However, co-expression of F and G along with M
revealed a shift in their distribution across the gradient, indicating association with M in VLPs.
Protein release was also altered depending on the context of viral proteins being expressed, with
F, G and nucleocapsid (N) protein reducing M release, and N release dependent on the co-
expression of M. Immunoelectron microscopy and density analysis revealed VLPs that were similar
to authentic virus. Differences in the budding dynamics of NiV proteins were also noted between
rMVA and plasmid based strategies, suggesting that over-expression by poxvirus may not be
appropriate for studying the details of recombinant virus particle assembly and release.
Conclusion: Taken together, the results indicate that NiV M, F, and G each possess some ability
to bud from expressing cells, and that co-expression of these viral proteins results in a more
organized budding process with M playing a central role. These findings will aid our understanding
of paramyxovirus particle assembly in general and could help facilitate the development of a novel
vaccine approach for henipaviruses.
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Background
Nipah virus (NiV) is a newly recognized, emerging para-
myxovirus capable of causing lethal infections in a
number of mammalian species including humans [1].
Together, with Hendra virus (HeV), they are members of
the recently created Henipavirus  genus within the Para-
myxoviridae family [2]. The type species HeV [3] appeared
first in eastern Australia in 1994 and was transmitted to
humans from infected horses (reviewed [4]). NiV was
identified later during an outbreak of severe encephalitis
in Malaysia and Singapore that began in 1998 and contin-
ued into 1999 and was primarily transmitted to humans
from infected pigs, although several additional animal
species were also noted to be infected (reviewed [5]). Sub-
sequent outbreaks of NiV in Bangladesh [6-10] and India
[11] have been smaller in scope but associated with higher
mortality and some human-to-human transmission [8].
Their broad species tropism coupled with their highly
pathogenic characteristics has distinguished the henipavi-
ruses from all other paramyxoviruses (reviewed in [12]).
The natural hosts of HeV and NiV appear to be several spe-
cies of flying foxes, bats in the genus Pteropus [13]. Evi-
dence of henipavirus infection of bats has been obtained
in Australia, Malaysia, Cambodia, and Thailand [14-17]
and virus has been isolated from bat urine and partially
eaten fruit [16,18]. Because of their availability from nat-
ural sources and relative ease of propagation and dissem-
ination, NiV and HeV have been classified as priority
pathogens by the Centers for Disease Control and Preven-
tion (CDC) and the National Institute of Allergy and
Infectious Diseases (NIAID). There are currently no
approved vaccines or effective therapeutics for the preven-
tion or treatment of NiV or HeV infection.
Like other paramyxoviruses, NiV and HeV are enveloped
with single-stranded negative-sense RNA genomes that
replicate in the cytoplasm [1,19]. Members of this family
include several well-known viruses such as measles virus
(MeV), Sendai virus (SeV), human parainfluenza viruses
(hPIV) types 1–4, simian virus 5 (SV5), Newcastle disease
virus (NDV), mumps virus, and respiratory syncytial virus
[19]. The genome encodes six principal viral proteins:
nucleocapsid (N) protein, phosphoprotein (P), matrix
(M), the fusion (F) and attachment (H, HN, G) envelope
glycoproteins, along with the viral RNA-dependent RNA
polymerase (L). Additional viral proteins include V, C,
and others that vary according to species [19]. Among the
paramyxoviruses, comparatively little is known about the
cell biology of the henipaviruses, but there have been sev-
eral significant advances made in recent years through the
analysis of the structure and function of several henipavi-
rus proteins expressed from cloned genes, particularly the
polycistronic P gene which encodes four proteins: P, V, C
and W that have been shown to modulate virulence by
abrogatingthe cellular interferon response [20-23]. Other
studies on the F and G envelope glycoproteins, which
together determine host range and cellular tropism
[24,25], have identified EphrinB2 as a key cellular recep-
tor for both NiV and HeV [26,27], and have also revealed
a unique F precursor cleavage and maturation process [28-
30]. However, an examination of henipavirus particle
assembly and roles the various viral proteins may play in
that biological process has not been described.
The assembly and morphogenesis of progeny virions
requires that viral proteins, including the envelope glyco-
proteins and ribonucleoprotein (RNP) complex, associate
at the plasma membrane for inclusion into budding viri-
ons. This association is thought to be mediated by the M
protein; however the details of this process are poorly
understood and seem to vary among viral species [31].
Recombinant MeV [32], SeV [33] and rabies virus [34]
that lack M are impaired in budding ability but remain
infectious as demonstrated by increased cell-cell fusion.
Recombinant expression of the M protein of SeV [35,36],
hPIV-1 [37], or NDV [38], in the absence of other viral
proteins, leads to budding of virus-like particles (VLPs).
Similar results have been observed for vesicular stomatitis
virus (VSV) [39-41] and Ebola virus (EBOV) [42-46]. In
addition, certain envelope glycoproteins also appear to
have intrinsic budding activity, as has been shown for SeV
F [35,36], the G protein of rabies virus (RV) and VSV
[47,48], and the envelope glycoprotein (Gp) of Ebola
virus [44,45,49]. In contrast, SV5 requires expression of M
along with N and at least one of its envelope glycoproteins
in order for efficient budding to occur [50].
NiV culture is restricted to BSL-4 containment and this
imparts significant limitations on experimentation aimed
at exploring the cell biology of the virus. To circumvent
this, we used recombinant gene expression systems, both
plasmid transfection-based and recombinant Modified
Vaccinia virus Anakara (MVA), to safely study the viral
proteins individually and together through the generation
of VLPs in cell culture. Both vaccinia virus and MVA have
been used in reverse genetics systems to generate negative-
sense RNA viruses, including paramyxoviruses, from
cDNA [51]. Vaccinia virus has also been employed in bud-
ding assays for both rhabdoviruses and filoviruses
[39,41,42,49], however certain features of MVA suggested
it may be a better platform for such assays. MVA is an
attenuated deletion mutant of Vaccinia virus that cannot
replicate in most mammalian cells [52]. The block in rep-
lication occurs during viral assembly, which allows for a
high level of gene expression without progeny virus pro-
duction and with less cytopathic effect [53]. Here we
describe the generation and characterization of NiV VLPs.
Our results demonstrate that NiV M possesses intrinsic
budding activity and can facilitate the inclusion of otherVirology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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viral proteins into VLPs. Both the F and G envelope glyco-
proteins could also be independently released from
expressing cells in association with membrane, however
co-expression of these viral proteins resulted in a reduc-
tion of the level of M budding perhaps by virtue of a more
organized assembly process with M playing a central role.
Sucrose density gradient analysis and immunoelectron
microscopy revealed particles consistent in density and
size with authentic NiV. These findings will aid our under-
standing of paramyxovirus particle assembly in general
and could help facilitate the development of novel vac-
cine approaches for henipaviruses.
Results
MVA expression of NiV proteins
We first sought to develop a NiV VLP expression system
using the MVA poxvirus as a means of gene delivery and
expression. Here, the NiV N, M, F and G ORFs were sub-
cloned into the pMC03-based vector [54] in which the
vaccinia virus early-late promoter was replaced with the
bacteriophage T7 promoter. These constructs were then
used to create the various rMVAs containing the individ-
ual NiV genes under the control of the T7 promoter. To
test for NiV protein expression, Vero cells were infected
with individual rMVAs expressing N, M, F, or G, along
with MVAGKT7 encoding the T7 RNA polymerase.
Infected cells were metabolically labeled overnight. Cell
lysates were prepared and the NiV proteins were immuno-
precipitated with NiV-specific polyclonal rabbit serum or
rabbit anti-F polyclonal serum (Fig. 1). Immunoprecipi-
tated proteins revealed bands corresponding to NiV N and
M (Fig. 1A, lanes 2 and 3) which migrated at the expected
apparent molecular weights of ~58 kDa (N) and ~42 kDa
(M) respectively [55,56]. The NiV F0 (~61 kDa), F1 (~49
kDa), and G (~74 kDa) shown in Fig 1A (lanes 5 and 7),
were found to be consistent with patterns reported previ-
ously [25].
In subsequent experiments to evaluate whether expres-
sion of NiV proteins can lead to VLP formation, cells were
infected with rMVAs and metabolically labeled for 44 h
followed by collection of both the cells and culture super-
natant. Vesicles in the culture supernatant were pelleted
by centrifugation through a 10% sucrose cushion and
then floated by centrifugation in a discontinuous sucrose
gradient as described in the Methods. Membrane-associ-
ated proteins were collected from the top of the gradient
and detected by immunoprecipitation and separation by
SDS-PAGE followed by autoradiography. While little
membrane-associated N was detected in culture superna-
tants, individual expression of M, F, and G resulted in
detectable membrane-associated protein release (Fig. 1B).
To characterize the protein release as genuine VLPs, the
culture supernatant of metabolically labeled cells express-
ing N, M, F, and G together was layered onto a 5–45%
sucrose gradient, which was then centrifuged to allow
membrane-associated proteins to migrate to their buoy-
ant density. Fractions of the gradient were then removed
MVA expression of NiV proteins results in protein release Figure 1
MVA expression of NiV proteins results in protein release. 
(A) Vero cells were infected with rMVAs expressing NiV N, 
M, F, or G, along with MVAGKT7 and then metabolically 
labeled. Lysates were immunoprecipitated with either rabbit 
anti-NiV polyclonal serum (N, M, G) or rabbit anti-F polyclo-
nal serum. (B) Vero cells were infected with rMVAs and 
MVAGKT7 and metabolically labeled. Released protein was 
purified by centrifugation through a 10% sucrose cushion fol-
lowed by flotation in a sucrose gradient. Proteins derived 
from cell lysates (L) or culture supernatants (S) were immu-
noprecipitated and analyzed as described above and in Meth-
ods. Lysate bands represent 1/20 of total lysate. (C) 
Supernatant from radiolabeled cells expressing N, M, F, and 
G was clarified and released protein was loaded onto a 5–
45% sucrose gradient followed by centrifugation for 16 h as 
described in Methods. Fractions were obtained and proteins 
were analyzed by immunoprecipitation. A portion of each 
fraction was used to determine density.Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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with a portion of each fraction set aside for sucrose density
determination. The proteins in the remaining portion of
the fractions were then detected by immunoprecipitation
followed by SDS-PAGE and autoradiography analysis.
NiV proteins were found predominantly in fractions 2
through 4, which corresponded to a density range of
1.12–1.19 g/ml (Fig. 1C). This density range was consist-
ent with the density reported for SeV and NDV VLPs
[35,36,38], as well as authentic NiV (see below). To exam-
ine the contribution of each viral protein to overall pro-
tein release, NiV proteins were expressed in different
combinations and their release was quantified. A release
of N was not detected when expressed alone, however co-
expression of M with N resulted in release of both proteins
into the supernatant (Fig. 2A). Quantified expression of M
with other viral proteins resulted in a reduction in the
mean M released (~12%) compared to its expression
alone; however this reduction did not reach statistical sig-
nificance among repeated experiments (Fig. 2B). We also
confirmed that expression of multiple proteins simultane-
ously did not reduce the overall N, M, F, or G expression
levels (data not shown). Quantitation of envelope glyco-
protein release revealed that approximately 11% of F and
5% of G was released when expressed alone (Fig. 2C).
NiV protein release and VLP production is not dependent 
on MVA infection
Although less cytopathic than its wild-type parent, MVA
retains the ability to block host protein synthesis and oth-
erwise interfere with normal cellular metabolism [57]. In
order to determine whether the protein release we
observed was an accurate reflection of NiV biology rather
than a potential artifact resulting from poxvirus infection,
we employed a transfection plasmid-based expression sys-
tem using the pCAGGS eukaryotic expression vector,
which has also been used in other paramyxovirus VLP
assays [35-38,50]. The NiV N, M, F, and G genes were sub-
cloned into the pCAGGS vector and expression was veri-
fied in separate experiments by immunoprecipitation
(data not shown).
To determine whether the various NiV proteins produced
by this method were also released from expressing cells,
cultures were transfected with individual plasmid con-
structs for 24 h, followed by metabolic labeling for
another 20 h. Cells and culture supernatants were har-
vested and processed as described above and in the Meth-
ods. We again observed membrane-associated release of
M, F and G, but no detectable release of N as predicted
(Fig. 3A). Immunoprecipitation analysis of M expressed
by plasmid-transfected cells consistently revealed a dou-
blet of bands that were both released into the culture
supernatant (Fig. 3A). When M was expressed by MVA, the
doublet was usually only revealed by Western Blot (data
not shown). We have been unable to determine the nature
of the doublet, but it could reflect a post-translational
modification of M. Although NiV M does contain a sec-
ond potential AUG start codon 36 nt downstream of the
Quantitated release of MVA-expressed NiV proteins Figure 2
Quantitated release of MVA-expressed NiV proteins. Cells were infected with rMVAs in order to express NiV proteins alone 
or in combination. Cells and supernatants were treated as in Fig. 1B. Membrane-associated protein release of (A) N, (B) M and 
(C) F and G was quantitated by densitometry. A representative experiment is shown for A, and the mean and standard devia-
tion of three or more experiments are shown in B and C.Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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first start codon [58], this does not account for the doublet
appearance because a truncation mutant that begins at the
second start codon, as well as HeV M, which lacks the sec-
ond AUG codon, also appear as doublets (data not
shown). Quantification of protein release revealed an
overall reduction in protein release compared to that seen
in the MVA system (Fig. 3B, compare with Fig. 2). Several
studies have provided evidence for a physical interaction
between paramyxovirus attachment and fusion proteins
[59-61]. For NiV F and G this interaction is apparent from
their ability to be co-precipitated without cross-linking
(Bossart and Broder, unpublished data). We therefore
sought to determine the effect of F and G co-expression on
their release. Expression of F and G together resulted in
greater release of both proteins together in comparison to
expression of each protein individually (Fig. 3C). This
observed increase of their release did not appear to be a
result of increased protein expression or cell-surface
expression (data not shown). We also noted that when N,
M, F and G were all co-expressed using equivalent
amounts of transfected plasmids, there was an overall
reduction in protein release from cells (data not shown).
Indeed, in certain other recombinant VLP expression sys-
tems, the amounts of transfected plasmids have been
adjusted in order to more accurately reflect or achieve cel-
lular expression levels of the individual viral proteins pro-
duced using infectious virus [36,38,50]. In an attempt to
increase protein release in our system, we performed sim-
ilar experimental variations in the amounts of tranfected
plasmids and estimated envelope glycoprotein expression
in authentic NiV infection as one third of M expression
and adjusted plasmid ratios accordingly [55,62,63], and
we further reduced N expression to 50 ng per well. How-
ever, even when the adjusted plasmid ratio was used, over-
all protein release remained low (Fig. 3D). We verified
that this was not due to a reduction of protein expression
due to multiple gene expression (data not shown), so we
interpret this as indicative of a more organized assembly
and budding process. In addition, the co-expression of N
and M resulted in the release of N but with modest release
of both proteins (Fig. 3E). This was in agreement with our
previous results obtained using the MVA expression sys-
tem, which demonstrated that M facilitated the release of
N. However, in contrast to the MVA expression system,
here we observed that N reduced overall M release. (Fig.
3E, compare with Fig. 2A and 2B).
NiV proteins are released in the absence of MVA Figure 3
NiV proteins are released in the absence of MVA. 293T cells were transfected with pCAGGS constructs containing NiV genes. 
(A) Protein released into the supernatant was purified by gradient centrifugation as described in Methods. Proteins were 
immunoprecipitated with MAbs F45G6 (anti-N), F45G5 (anti-M) or rabbit polyclonal anti-serum against NiV F or HeV G. (B) 
Protein released as in (A) was quantitated by densitometry. The mean and standard deviation of three or more experiments 
are shown. ND = not detectable. Release of protein from cells expressing combinations of F and G (C) N, M, F, and G (D) or 
N and M (E) are shown along with the percent protein released. N was not immunoprecipitated in D to allow visualization of 
F0. Quantitation for C was performed on a lighter exposure. Proteins derived from cell lysates (L) or culture supernatants (S) 
are indicated. Lysate bands represent 1/6 of total lysate. Representative experiments are shown.Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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Specific M release and kinetic analysis
In order to ensure that NiV M release was accomplished by
a mechanism specific to itself, release of NiV M was again
examined but in parallel with SV5 M, which requires co-
expression of N and one of the envelope glycoproteins in
order to form VLPs that are released into the culture super-
natant [50]. Here the analysis of culture supernatants
showed release of NiV M but no detectable release of SV5
M (Fig. 4A), suggesting that the observed release of NiV M
was specific to its biological properties and not due to a
non-specific mechanism such as cell lysis. In this respect,
NiV M was similar to the M proteins of SeV, NDV, and
hPIV1, all of which have been reported to form VLPs in
the absence of other viral proteins [35-38].
We also wanted to explore the kinetics of M expression
and its eventual release from cells. For this analysis, plas-
mid-transfected cells were starved for 45 min, 35S-pulsed
for 15 min, and then chased for varying lengths of time up
to 32 h. At each time point cells and supernatants were
harvested. Vesicles released into the supernatant were
purified by centrifugation through a 10% sucrose cushion
followed by sucrose gradient flotation. M derived from
supernatants or cell lysates was immunoprecipitated with
a monoclonal antibody and visualized by SDS-PAGE and
autoradiography. Percent M release was quantitated by
densitometry. The presence of membrane-associated pro-
tein in the supernatant was barely detectable at 2 h with
0.3% release, but then readily detected at 4 h with 1.7%
release (Fig. 4B). Maximum M release of 27.4% was
observed by 16 h.
Electron microscopy analysis of VLPs
The biochemical analysis of the NiV proteins released
from expressing cells in a membrane-associated manner
suggested that VLPs were being generated. To analyze the
released material visually, VLPs were prepared and iso-
lated by sucrose gradient floatation and the resulting frac-
tions were immunolabeled using antibodies against NiV
M or HeV G followed by a secondary antibody conjugated
to gold beads. After negative staining, the samples were
examined by immunoelectron microscopy. Expression of
NiV M alone resulted in the release of VLPs that contained
M and varied in size from approximately 100 to 700 nm
in diameter (Fig. 5A–C). Expression of NiV N, M, F, and G
resulted in the release of VLPs with detectable M (Fig. 5D)
or G (Fig. 5E) with a diameter of approximately 100 to
300 nm. The size of the VLPs observed is consistent with
observations made on authentic NiV virions which have
been reported with sizes ranging from 40 to 1900 nm
[64,65].
Interaction between proteins during VLP formation
In order to further investigate the interaction of F and G
with M during VLP release we performed sucrose density
gradient analyses to determine whether the buoyant den-
sity of released particles varied depending on the viral pro-
teins present. M produced alone, F produced with G, or
the combination of N, M, F and G were expressed in cells,
metabolically labeled, and the culture supernatants were
harvested and layered onto 5–45% continuous sucrose
gradients. After centrifugation, the gradients were frac-
tionated and analyzed by immunoprecipitation and SDS-
PAGE. The M protein was again recovered predominantly
in fractions 3 to 5, corresponding to a density range of
1.11–1.18 g/ml (Fig. 6A and 6B). We noted that the M
protein could also be found in less dense fractions, espe-
cially when it was expressed in the absence of any other
viral proteins. When F was co-expressed along with G,
both proteins were recovered predominantly in fractions
1 to 3, which correspond to a density of 1.18–1.21 g/ml
(Fig. 6A and 6B). However, the co-expression of N, M, F,
Comparison of NiV M release with SV5 M and kinetics of NiV M release Figure 4
Comparison of NiV M release with SV5 M and kinetics of NiV M release. (A) Culture supernatants were analyzed for release of 
either NiV or SV5 M. Released protein was treated as described in Methods and proteins were immunoprecipitated using 
either rabbit anti-NiV polyclonal serum or MAb M-h (anti-SV5 M). Image shown is over-exposed to show contrast. (B) Cells 
expressing NiV M were starved for 45 min, 35S-pulsed for 15 min, then chased with DMEM-10 for times indicated. Released 
protein was purified and protein derived from lysate or supernatant was immunoprecipitated with MAb F45G5. Percent pro-
tein release was quantitated by densitometry. Proteins derived from cell lysates (L) or culture supernatants (S) are indicated. 
Lysate bands represent 1/6 of total lysate.Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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and G led to a greater concentration of M in fraction 4
and, importantly, this also resulted in a shift of the frac-
tionation profile of F and G distribution to fractions 3 to
5 (Fig. 6A and 6B). This density range was also consistent
with the previous results obtained using rMVAs (Fig. 1C).
Further, sucrose density gradient analysis of authentic
infectious NiV revealed peak virus concentration at a den-
sity of 1.15 g/ml, which corresponded well with our VLP
results (Fig. 6C). Taken together these findings suggest
that although F and G can direct budding when produced
alone, the co-expression of M facilitates F and G incorpo-
ration into VLPs with a density that is more consistent
with that of an authentic virion.
Discussion
The advent of reverse-genetics coupled with the in vitro
techniques of VLP production has made it possible to
examine the cell biology of viruses in increasing detail.
However, certain highly pathogenic viruses such as the
henipaviruses are restricted to BSL-4 containment, mak-
ing such studies impractical, and in the absence of a hen-
ipavirus reverse-genetics system there are considerable
obstacles in place to dissecting out the details of an indi-
vidual protein's role(s) in particle formation. To circum-
vent some of these obstacles, we have established a VLP
system to allow us to investigate certain details of NiV
assembly and release. Our first attempts made use of a
recombinant poxvirus platform using MVA because of its
high efficiency in gene delivery and expression, and for its
reduced level of cytopathic effect as compared to vaccinia
virus. Further, poxviruses have been successfully
employed in reverse-genetics systems and virus budding
assays with success [39,41,42,49,51]. Using rMVAs to
deliver NiV genes we observed membrane-associated
release of M, F, and G. The ability of an M protein to be
released from cells when expressed alone has also been
observed for some other paramyxoviruses including SeV
[35,36], hPIV-1 [37], and NDV [38], as well as viruses in
other related virus families including Ebola [42-45] and
VSV [39-41]. In addition, Ciancanelli and Basler have
recently independently reported that expression of NiV M
leads to VLP formation [66]. Release of F when expressed
alone has been observed for SeV [35,36], and release of
HN has been noted for NDV [38]. Ebola virus [44,45,49],
VSV [47,48], and rabies virus [47,48] each contain a single
envelope glycoprotein that can also direct budding of ves-
icles, thus our observations here that NiV F and G can be
independently released is not unprecedented. In contrast
to these other viruses, individual viral proteins expressed
alone from SV5 are not released from cells, and particle
Immunoelectron microscopy shows particles consistent in size with authentic NiV virions Figure 5
Immunoelectron microscopy shows particles consistent in size with authentic NiV virions. VLPs released from transfected 
293T cells were purified by gradient centrifugation, labeled by immuno-gold, negatively stained, and viewed by electron micro-
scopy as described in Methods. VLPs were derived from cells that expressed M (A to C) or N, M, F, and G (D and E). Immu-
nolabeling against M was done using MAb F45G5 (A to D) and G was detected with mouse anti-HeV G polyclonal serum (E). 
Bars represent 100 nm. Specificity of primary and secondary antibodies was demonstrated by their failure to stain negative 
controls (not shown).Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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formation requires the expression of M, N, and at least
one envelope glycoprotein in order for any significant VLP
release to occur [50].
Typically, viruses rescued using reverse-genetics tech-
niques that employ vaccinia virus are subsequently puri-
fied from contaminating poxvirus and amplified by
growth in cell culture. In such cases, the alteration of cel-
lular metabolism by vaccinia virus is therefore of little
concern because it is ultimately unimportant to the out-
come. However, we were concerned that the effects of
MVA infection might confound the interpretations of our
VLP studies. Therefore, we employed a eukaryotic plas-
mid-based system as a means of gene expression in order
to determine whether the results obtained using rMVAs
faithfully reflected NiV biology.
When individual NiV proteins were produced in cells by
transfection, M, F and G were each independently released
into culture supernatants in a membrane-associated man-
ner. In contrast, N was not detected in culture superna-
tants, as predicted, and these results were in agreement
with those observations made using rMVAs. However, the
percent of protein released was higher in the MVA system,
which may reflect an effect of MVA on cellular metabo-
lism or overall expression levels of the individual genes.
When M was expressed in combination with various NiV
proteins using rMVAs we observed little change in M
release, irrespective of which other NiV proteins were
present. Expression of M with N enabled greater release of
membrane-associated N, which is consistent with the
model that M and N interact, and that this interaction
facilitates the incorporation of the genome into budding
virions [31,37,67]. The dynamics of protein release were
somewhat different when a plasmid-based transfection
and expression system was used. Under these conditions,
we found that co-expression of M with N, or M with N, F
and G lead to a reduction in M release. We obtained a sim-
ilar result when F and M were co-expressed (data not
shown). We also found that F and G co-expression lead to
greater release of both proteins than when either was
expressed independently. Notably, in either the MVA or
plasmid-based expression systems we predominantly
detected F0 in both cell lysates and supernatants (Fig. 1B
and Fig. 3A, C–D). In contrast, NiV virions appear to con-
tain completely processed F [68]. The reason for this dif-
ference is not known, but we and others have consistently
observed greater levels of F0 when recombinant expression
systems are employed which could bias its incorporation
into particles [25,28,69], or perhaps additional viral fac-
tors present during natural viral replication result in
greater F processing or a biased incorporation of proc-
essed F.
Density analysis of VLPs released from transfected cells  expressing NiV proteins Figure 6
Density analysis of VLPs released from transfected cells 
expressing NiV proteins. (A) Clarified culture supernatants 
from cells expressing different combinations of NiV proteins 
were layered onto 5–45% sucrose gradients and centrifuged. 
Fractions were immunoprecipitated with MAbs F45G6 (ant-
N), F45G5 (anti-M) or rabbit polyclonal anti-serum against 
NiV F or HeV G. A portion of each fraction was used to 
determine density. Densitometry analysis of the gels shown 
in (A) was used to determine the quantitative distribution of 
proteins (B). Where more than one protein was expressed, 
the protein analyzed by densitometry is indicated by paren-
theses. (C) Supernatant from cells infected with NiV was lay-
ered onto a 5–45% sucrose gradient and centrifuged. RNA 
was extracted from fractions and used for real-time PCR. 
The threshold cycle (Ct) value was used as a proxy for virus 
concentration.Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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The context-dependent variations in protein release and
buoyant density suggest that the viral proteins interact
either directly or indirectly to orchestrate the particle bud-
ding process. The differences observed in the protein
release when a comparison is made between the trans-
fected plasmid-based and rMVA systems are likely a result
of the alterations of cellular metabolism brought about by
MVA infection. Although VLPs can be produced using
either system, our results suggest that the two methods
have different applications. We believe the cell biology of
NiV is more accurately reflected in the plasmid-based
transfection system in the absence of poxvirus infection.
Because of the efficiency of gene delivery and expression,
and the greater percentage of viral protein released, the
MVA system could be more useful when quantity of VLPs
is of primary concern. VLPs have been reported to elicit a
protective immune response against Ebola and Marburg
viruses in animal models [70], and might serve as a more
efficient method of NiV VLP production for immuniza-
tion studies or perhaps as a potential livestock vaccine,
which we are exploring.
To ensure that NiV M was not released into culture super-
natants by a non-specific means such as cell lysis, we
assayed SV5 M in parallel as a control. As expected, we
detected the release of M for NiV but not for SV5. How-
ever, SV5 M budding could readily be detected when it
was co-expressed with its HN, F, and N genes (data not
shown). Pulse-chase analysis of NiV M expression
revealed detectable release from expressing cells by 2 to 4
h with a maximal release of at least 27% by 16 h. This per-
centage of release is, of course, greater than that observed
during standard budding assays, which were not per-
formed as a pulse-chase. The percentages of protein
release reported in our budding assays here, as well as for
SeV [35,36] and SV5 [50] have also been reported as non-
pulse-chased systems. As a result, any nascent protein pro-
duced in the cell is included in the overall calculation.
This method is useful as a relative measure between
groups, but probably underestimates the true budding
efficiency. Here, pulse-chase not only reveals the timing of
release but also likely gives a more accurate picture of the
kinetics of M production and its ultimate destination, that
is its release from producing cells.
Ultrastructural studies of NiV have revealed pleiomorphic
virions that range from 80–1900 nm [64,65]. Here, when
M was expressed alone or along with N, F and G, we
observed VLPs containing the various proteins by
immuno-gold labeling and electron microscopy. The
VLPs ranged in size from approximately 100 to 700 nm,
consistent with the range reported for actual virus. Using
both the MVA and transfection systems we observed NiV
proteins migrating as membrane vesicles at a density
range of 1.11–1.19 g/ml. Authentic NiV migrated to a sim-
ilar density range with peak detection at 1.15 g/ml. This
range is consistent with the density of SeV and NDV VLPs
as well as SeV virions [35,36,38]. Using a plasmid trans-
fection system we further evaluated the release of M alone,
and with co-expression of N, F, and G. Although a greater
percentage of M was detected in additional fractions when
expressed alone, it was predominately concentrated in
fractions 3 to 5 when co-expressed along with N, F, and G.
Particles containing F and G migrated to denser fractions
when additional NiV proteins were absent, but the posi-
tion of both proteins in the gradient shifted to fractions 3
to 5 when M was present, suggesting that M interacts with
F and G either directly or indirectly during assembly to
facilitate the incorporation the envelope glycoproteins
into the particles. The reason for the greater density of par-
ticles containing only F and G is unknown, but it is likely
a reflection of altered lipid or protein incorporation rela-
tive to particle size. Taken together, the density and
ultrastructural characteristics of the membrane-associated
NiV proteins reported here are suggestive of authentic VLP
formation.
Ciancanelli and Basler recently observed NiV VLPs when
M was expressed alone or with envelope glycoproteins
[66], which is supportive of our data. Although they did
not perform quantitative analysis in their study, M release
was apparently unaffected by the presence of one or both
of the envelope glycoproteins. As mentioned above, in
our hands plasmid-based co-expression of M and F
resulted in a distinct reduction in M release. This apparent
discrepancy may be attributable to differences in the VLP
purification techniques, especially in our inclusion of an
additional particle flotation step. Another difference
between the two studies is our inclusion of the N protein,
which was found to also reduce M release and this was not
examined in the Ciancanelli and Basler report. VLP forma-
tion has been evaluated for other paramyxoviruses includ-
ing SeV, hPIV-1, SV5, and NDV [35-38,50]. Of these, only
SV5, SeV, and NDV have been addressed with any quanti-
tative assessment. Two independent studies of SeV VLP
formation reported that M and F can each be released
independently and that when M and F are expressed
together that the percentage of each protein released is
greater [35,36]. However the percent of protein released
differed dramatically between the studies with Takimoto
et al. [35], reporting approximately 50% of M released and
Sugahara et al. [36], reporting 14.5% of M released. Using
avian cells and a pulse-chase system, Pantua et al. reported
that NDV M is both necessary and sufficient for VLP
release, with solo expression of NDV M resulting in 90%
release efficiency [38]. Whereas SV5 VLP release was most
efficient (32% of M released) when N, M, F, and HN were
expressed together [50], there was a decrease in M release
when the equivalent SeV or NDV proteins were co-Virology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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expressed [36,38], which is comparable to our results
observed with NiV N, M, F and G.
Sugahara et al. [36] have also shown that expression of the
C protein with N, M, F, and HN leads to an increase in VLP
release by 2- to 3-fold. This increase was subsequently
shown to be due to the interaction of C with AIP1/Alix, a
cellular protein involved in multivesicular body forma-
tion; however an interaction between AIP1/Alix and mea-
sles C was not detected, suggesting that this mechanism of
budding is not applicable to all paramyxoviruses [71].
Nevertheless, this raises the possibility that additional NiV
proteins not evaluated here may increase VLP release, but
further experiments will be required to determine whether
this is the case. It is also important to recognize that
because the various studies on several paramyxovirus
VLPs each employed slightly differing methodologies in
their analysis, the calculated percentage of released pro-
teins among the various reports are not directly compara-
ble. However, the qualitative differences seen between
these viruses suggest that beneath the generalized model
of paramyxovirus assembly and budding lie differences in
the specific mechanisms employed, and these differences
remain to be determined.
Conclusion
Nipah Virus-like particles can be produced by recom-
binant gene expression. The matrix, fusion, and attach-
ment proteins each possess some budding ability of their
own; however, the matrix protein appears to play a central
role in virus particle assembly and release from expressing
cells. The system developed here along with the present
findings will help facilitate studies on NiV morphogenesis
in greater detail, and provide a platform for exploring the
nature and role of potential host factors in the virus bud-
ding process. Importantly, the VLP system detailed here
also allows for the examination of recombinant particle
assembly and release outside high-level biological con-
tainment.
Methods
Cell lines
Vero cells, provided by Alison O'Brien (Uniformed Serv-
ices University), and chicken embryo fibroblast cells
(Charles River Laboratories, Inc, Wilmington, MA) were
maintained in Eagle's minimal essential medium (Quality
Biologicals, Gaithersburg, MD) supplemented with 10%
cosmic calf serum (Hyclone, Logan, UT), 2 mM L-
glutamine, and 100 units/ml penicillin and streptomycin
(Quality Biologicals, Gaithersburg, MD) (EMEM-10).
293T cells were maintained in Dulbecco's modified
Eagle's medium (Quality Biologicals, Gaithersburg, MD)
supplemented as described above (DMEM-10). All cul-
tures were maintained at 37°C in 7.5% CO2.
Antibodies
The following antibodies were used in immunoprecipita-
tions: Polyclonal rabbit antiserum against NiV F was
obtained by immunization of rabbits with a synthetic
peptide of the following sequence: CNTYSRLEDR-
RVRPTSSGDL, which corresponds to the cytoplasmic tail
of NiV F. The peptide was conjugated to keyhole limpet
hemocyanin (KLH) for immunization. Monoclonal anti-
bodies (MAbs) F45G5 (anti-M) and F45G6 (anti-N) were
kindly provided by Jody Berry and Hana Weingartl
(National Centre for Foreign Animal Disease, Canadian
Food Inspection Agency). MAb M-h (anti-SV5 M) was
kindly provided by Robert Lamb (Northwestern Univer-
sity). Mouse antiserum specific for HeV G was provided by
Andrew Hickey (Uniformed Services University). Polyclo-
nal serum from a rabbit immunized with gamma-irradi-
ated NiV and from a rabbit immunized with soluble HeV
G were also used.
Plasmid and recombinant MVAs
A system for recombinant gene expression using modified
vaccinia virus Ankara (MVA) has been described [54].
pMC03ΔE/L, which was made by removing the vaccinia
virus promoter from pMC03 by ligation of the vector after
PstI digestion, was provided by Katharine Bossart (CSIRO
Livestock Industries, Australian Animal Health Labora-
tory). To introduce the bacteriophage T7 promoter into
the vector, complementary oligonucleotides 5'-
ggaaattaatacgactcactatagggagaccacaacggtttaaacg-
gcgcgccgga (T7S) and 5'-
gatctccggcgcgccgtttaaaccgttgtggtctccctatagtgagtcgtattaatttc-
ctgca (T7AS) were mixed in equal molar amounts, heated
to 65°C, then allowed to cool and ligated into the PstI and
BglII sites of pMC03ΔE/L to form pMC03T7.
The NiV N ORF was PCR amplified from pCP629 (NiV N
gene in pFastBac HTc) using primers 5'-GTTTAAACCAC-
CATGAGTGATATCTTTG (NIVNS) and 5'-GTTTAAACT-
CACACATCAGCTCTG (NIVNAS). The NiV M ORF was
PCR amplified from pCP630 (NiV M gene in pFastBac
HTa) using primers 5'-GTTTAAACCACCATGGAGCCG-
GACATC (NIVMS) and 5'-GTTTAAACTTAGCCCTTTA-
GAATTCTC (NIVMAS). The NiV F ORF was PCR amplified
from pMC02 NiV F [25] using the primers 5'-GTTTAAAC-
CACCATGGTAGTTATACTTGAC (NF2) and 5'-
GGCGCGCCCTATGTCCCAATGTAGTAG (NFAS2). The
NiV G ORF was PCR amplified from pMC02 NiV G [25]
using the primers 5'-GTTTAAACCACCATGCCGGCA-
GAAAAC (NIVGS) and 5'-GTTTAAACTTATGTACATT-
GCTCTGG (NIVGAS). PCR was done using Accupol DNA
polymerase (PGS Scientifics Corp., Gaithersburg, MD)
with the following settings: 94°C for 5 min, then 25 cycles
of 94°C for 1 min, 55°C for 2 min, then 72°C for 3 min.
The resulting PCR products were sub-cloned into pCRII-
Blunt-TOPO (Invitrogen, Carlsbad, CA). TOPO constructsVirology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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were digested with PmeI or PmeI and AscI, as appropriate,
and inserted into PmeI or PmeI-AscI sites in pMC03T7.
The pCAGGS/MCS eukaryotic expression vector has been
described previously [72,73]. In order to introduce an AscI
site into pCAGGS, 128 pmol of the oligonucleotide 5'-
TCGACGGCGCGCCG (CAG1) was heated to 65°C,
allowed to cool, and then ligated into the XhoI site of
pCAGGS/MCS to form pCAGGS-AscI. The ORFs for NiV
N, M, and G, were digested from pMC03T7 as PmeI frag-
ments and ligated into the pCAGGS SmaI site. The ORF
for NiV F was digested from pMC03T7 as a PmeI-AscI frag-
ment and ligated into the pCAGGS-AscI SmaI-AscI site.
pCAGGS-SV5 M was kindly provided by Robert Lamb.
To create recombinant MVAs, chicken embryo fibroblasts
(CEFs) were infected with wild-type MVA at a multiplicity
of infection (MOI) of 0.1. At 2 h post-infection, the CEFs
were transfected with 8 μg of the appropriate pMC03T7
construct using Profection Mammalian Transfection Sys-
tem – Calcium Phosphate (Promega, Madison, WI). At 4
hr post-transfection, cells were washed, given fresh
EMEM-10, and then incubated for 3 days at 37°C. Cells
were harvested by scraping, pelleted, and then resus-
pended in 0.5 ml EMEM-2.5 as crude recombinant virus.
After 3 cycles of freezing and thawing, virus was diluted
and CEF monolayers were infected overnight at 37°C.
Monolayers were then overlaid with EMEM-10 containing
1% low-melting point agarose (Invitrogen, Gaithersburg,
MD) and incubated for 2 days. A final overlay of EMEM-
10 containing 1% low-melting point agarose and 0.2 mg/
ml 5-bromo-4-chloro-3-indolyl-β-D-glucuronic acid (X-
Gluc) (Clontech, Palo Alto, CA) was added to the monol-
ayers and over the following 72 h cells that showed blue
staining were picked, resuspended in 0.5 ml EMEM-2.5,
and used for repeated positive selection. After 5 or more
rounds of purifying positive selection, recombinant MVAs
were amplified in CEFs to make crude stocks. Recom-
binant MVA expressing the bacteriophage T7 RNA
polymerase (MVAGKT7) was provided by Gerald R.
Kovacs (National Institutes of Health, Bethesda, MD).
Transfection, MVA infection, and metabolic labeling
293T cells in 6-cm wells were transfected in duplicate with
pCAGGS constructs using FuGene 6 transfection reagent
(Roche, Indianapolis, IN) according to the manufacturer's
instructions. Unless otherwise specified, 1 μg of each plas-
mid was used per well. Empty vector was used to make the
total DNA amount 4 μg/well. Vero cells were infected with
recombinant MVAs at an MOI of 3–5 in a minimal vol-
ume of EMEM containing 2.5% serum. At 24 h post trans-
fection or 6 h post infection, cells were overlaid with
methionine-cysteine-free minimal essential medium
(MEM) (Invitrogen, Gaithersburg, MD) containing 2.5%
dialyzed fetal calf serum (Invitrogen, Gaithersburg, MD)
and 100 μCi/ml 35S-cys/met Redivue Promix (Amersham
Pharmacia Biotech, Piscataway, NJ), and incubated at
37°C for transfected cells, or 31°C for infected cells. For
pulse-chase labeling, cells were washed then starved in
methionine-cysteine-free MEM for 45 min followed by
metabolic labeling as, as described above, for 15 min.
Cells were washed once then chased with DMEM-10.
Immunoprecipitation
Cells were harvested by scraping, pelleted by centrifuga-
tion at 5000 × g for 5 min, and then washed once with PBS
and pelleted again. The pellet was resuspended in 200 μl
lysis buffer (100 mM Tris-HCl, pH 8.0; 100 mM NaCl;
1.0% Triton-X 100) containing Complete, Mini protease
inhibitors at a 1× concentration (Roche, Indianapolis,
IN), and incubated on ice for 10 min. After removing
nuclei by centrifugation, lysates were pre-cleared by incu-
bation with Protein G-Sepharose (Amersham Pharmacia
Biotech, Piscataway, NJ) for 30 min. Lysates derived from
a VLP detection assay were frozen at -80°C until immuno-
precipitation. Typically 1–2 μl of appropriate antiserum
was used for each sample and antisera and lysates were
incubated at 4°C overnight, followed by addition of Pro-
tein G-Sepharose for 45 min. Protein G beads were
washed twice with lysis buffer followed by one wash with
lysis buffer containing 0.1% sodium deoxycholate and
0.1% SDS. Proteins were separated either by SDS-polyacr-
ylamide gel electrophoresis (SDS-PAGE) on a 10% poly-
acrylamide gel, or by a NuPAGE Novex 4–12% Bis-Tris gel
(Invitrogen, Gaithersburg, MD) and visualized by autora-
diography.
VLP assay
293T cells were transfected, and Vero cells were infected
with recombinant MVAs, as described above. At 20–24 h
p.t. or 48 h p.i., the cell culture medium was removed,
clarified, and then centrifuged through a cushion of 10%
sucrose (w/vol) in NTE (100 mM NaCl; 10 mM Tris-HCl,
pH 7.5; 1 mM EDTA) at 200,000 × g for 2 h at 4°C. The
resulting pellet was re-suspended in 4 ml NTE and 1.3 ml
80% sucrose. A discontinuous sucrose gradient was
formed by overlaying with 1.8 ml 50% followed by 0.6 ml
10% sucrose in NTE. The gradient was centrifuged at
200,000 × g for 16 h at 4°C in a SW50.1 rotor. Typically,
two 0.7 ml fractions were removed from the top of the gra-
dient, diluted with 2× lysis buffer, and analyzed by immu-
noprecipitation. The two fractions were combined during
the first wash after Protein G-Sepharose addition. Proteins
from 1/20 of cell lysates from MVA infections, and half of
cell lysates from transfected cells, were used for immuno-
precipitation. For samples derived from transfection, 1/3
of the sample was loaded on gels (equivalent to 1/6 total
lysate). Release efficiency was quantified by performing
densitometry analysis on scanned film images using
AlphaEaseFC software (Alpha Innotech Corporation, SanVirology Journal 2007, 4:1 http://www.virologyj.com/content/4/1/1
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Leandro, CA). Percent release was calculated as the frac-
tion of protein derived from the supernatant divided by
total protein detected (total lysate + supernatant).
Equilibrium centrifugation
Clarified culture supernatants of MVA-infected Vero cells
were centrifuged at 200,000 × g for 2 h at 4°C. The result-
ing pellet was resuspended in 200 μl NTE and added to
the top of a continuous gradient of 5–45% sucrose. Clari-
fied supernatants from transfected cells were added
directly to the gradient. The gradient was centrifuged in an
SW40 Ti rotor at 200,000 × g for 16 h at 4°C. Fractions
were collected from the bottom and 50 μl of each fraction
was set aside for density measurement. The remainder of
each fraction was combined with 4× lysis buffer (pH 7.5)
and immunoprecipitated as described. Density was deter-
mined based on refractive index as measured with a refrac-
tometer. Culture supernatants of NiV-infected Vero cells
were clarified at 20,000 × g for 10 min at room tempera-
ture and 100 μl of clarified supernatant containing
approximately 106 TCID50 was added to the top of a con-
tinuous gradient of 5–45% sucrose. The gradient was cen-
trifuged in an SW41 Ti rotor at 200,000 × g for 16 h at
4°C. Fractions were collected from the bottom and 50 μl
of each fraction was set aside for density measurement. A
portion (140 μl) of each fraction was extracted using the
QIAamp Viral RNA Mini kit (Qiagen GmbH, Hilden) and
extracted RNA was analyzed by quantitative real-time PCR
as previously described [74]. Threshold cycle (Ct) values
were used as a proxy for virus concentration and density
was determined based on refractive index as measured
with a refractometer.
Electron microscopy
VLPs released from transfected 293T cells into the culture
supernatant were prepared as described above except the
top 1.4 ml of the flotation gradient was mixed with 3 ml
of PBS and centrifuged for an additional 2 h after which
the pellet was resuspended in 60 μl PBS. VLPs were
adsorbed onto carbon-coated parlodion copper grids and
immunolabeled using either polyclonal HeV G-specific
mouse antiserum or anti-NiV M monoclonal antibody
F45G4, followed by secondary antibody conjugated to 12
nm gold beads. For detection of M, immuno-labeling was
done in the presence of 0.05% saponin. Samples were
negatively stained with 1% uranyl acetate and examined
with a Hitachi 7600 transmission electron microscope
operated at 80 kV.
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